scholarly journals Using Research Review Articles to Answer Clinical Questions: A Guide to Finding and Evaluating Scholarly Work

1978 ◽  
Vol 42 (2) ◽  
pp. 439-480 ◽  
Author(s):  
Wilma J. Knox

The literature published during 1973 on alcoholics in the United States was examined for objective psychological test data or behavioral measurements. Information was grouped according to problem area and included tests employed, significant findings, critical comments, and inferences for therapy and research. Review articles of 1973 are listed in an appendix.


2020 ◽  
Vol 3 (3) ◽  
Author(s):  
Yu. B. Melnyk

Dear Readers, We are honored to publish the International Journal of Education and Science (IJES), Vol. 3, No. 3, 2020. IJES is an academic periodical peer-reviewed indexed Journal that provides a scientific platform for presenting and discussing new trends and issues in Social and Behavioral Sciences. Since 2018, the Journal has published more than 200 manuscripts, including: Original Research, Review Articles, Brief Reports, Conference Abstracts, Reviews, Letters to the Editor. IJES Editorial Board includes the most authoritative scientists from 14 countries, 5 continents in the fields of Education, Psychology, Economics, Medicine. IJES is presented in 15 international scientometric databases, repositories and search engines: Crossref System, Google Scholar, Kopernio (USA); Publons (New Zealand); Scilit (Switzerland); ROAD (France); Index Copernicus International (Poland), etc. Indexed in the ICI Journals Master List ICV 2019: 80.33. From the second half of 2020, the IJES Editorial Board decided to replace one of the scientific directions of the Journal with another more specialized one (Medicine for Law). This is due, on the one hand, to the need for a certain specialization of the Journal, on the other – allows us to discuss new trends in interdependent areas: Pedagogy – Psychology, Economics – Law, which are included in the Social and Behavioral Sciences. So, from 2021 this international Journal is intended for professionals and researchers in scientific fields: Education, Psychology, Economics, Law. On behalf of the IJES Editorial Board, I personally would like to thank all the members of the Editorial Board who represented the Journal in the field of Medicine during these years. As the Publisher of the IJES, KRPOCH Publishing invited these members of the Editorial Board to continue their cooperation as members of the Editorial Board of the International Journal of Science Annals. IJES provides immediate Open Access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. All Articles apply under the terms of the Creative Commons Attribution License (CC BY 4.0). The Journal publishes Review Articles and Original Research, Letters to the Editor, and Reviews. A total of fourty five manuscripts were submitted for this issue, and each article was subjected to a doubleblind peer review process by reviewers specializing in the relevant field. At the end of the review process, five high quality research papers were selected and accepted for publication in this issue. Accordingly, the purpose of this issue is to enable researchers to share the results of their academic research. The articles discuss various research topics. We would like to thank all the Authors who submitted their manuscripts and to the IJES Editorial Board, which worked on this issue.


2005 ◽  
Vol 39 (7-8) ◽  
pp. 1286-1295 ◽  
Author(s):  
Stephen M Setter ◽  
Jason L Iltz ◽  
Jack E Fincham ◽  
R Keith Campbell ◽  
Danial E Baker

OBJECTIVE To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED). DATA SOURCES Primary research and review articles were identified through a search of ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts (1990–August 2004). The following search terms were used in the Medicine Dentistry and Pharmacology, Toxicology, and Pharmaceutical Sciences subcategories: phosphodiesterase 5 inhibitor, PDE5 inhibitor, erectile dysfunction, sildenafil, vardenafil, tadalafil, prostatectomy, and diabetes. Web of Science (1990–August 2004) was used to search for additional abstracts using the same search terms as above. The package inserts for sildenafil, vardenafil, and tadalafil were also consulted. STUDY SELECTION AND DATA EXTRACTION All identified research, review articles, and abstracts were assessed for relevance, and all relevant information was included. Priority was given to the primary medical literature and clinical trial reports. DATA SYNTHESIS ED is a common disorder in males with increased prevalence associated with age and presence of cardiovascular disease, prostatectomy, or diabetes mellitus. Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors currently available for treatment of ED. Their pharmacology and pharmacokinetics vary slightly, but with potentially important clinical differences in duration of activity; all have similar clinical efficacy and adverse effect profiles in patients with ED of various causes. CONCLUSIONS Sildenafil, vardenafil, and tadalafil are safe and effective PDE5 inhibitors for the treatment of ED.


2007 ◽  
Vol 143A (11) ◽  
pp. 1258-1259
Author(s):  
Anne C.-H. Tsai ◽  
John P. Johnson

2007 ◽  
Vol 143A (11) ◽  
pp. 1256-1257 ◽  
Author(s):  
Horacio Rivera ◽  
Maria G. Domínguez

ASHA Leader ◽  
2013 ◽  
Vol 18 (3) ◽  
pp. 60-60

Nominate Clinical Questions for Systematic Reviews


Sign in / Sign up

Export Citation Format

Share Document